Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

accessnewswire.com
AARD The article details an investigation into Aardvark Therapeutics due to a pause in a late-stage trial for a rare disease treatment. The pause was caused by heart-related side effects observed in a healthy volunteer study, leading to a significant drop in the company's stock price.

Aardvark Therapeutics, Inc. (AARD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / March 24, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aardvark Therapeutics, Inc. ("Aardvark" or "the Company") (NASDAQ:AARD). Investors who purchased Aardvark securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AARD.

Aardvark Investigation Details

On February 27, 2026, Reuters published a report on Aardvark titled: "Aardvark pauses late-stage trial testing rare disease treatment." According to the report, "The company said it decided to pause the late-stage study ‘out of an abundance of caution' after it found some heart-related side effects during safety monitoring in a healthy volunteer study in patients receiving higher‑than‑planned doses of the treatment." Following this news, Aardvark's stock price dropped by more than 47.3% in after-hours trading that same day.

What's Next for Aardvark Investors?

If you are aware of any facts relating to this investigation or purchased Aardvark securities, you can assist this investigation by visiting the firm's site: bgandg.com/AARD. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Aardvark Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Aardvark Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller

Bronstein, Gewirtz & Grossman, LLC

917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC